Celularity Inc - Ordinary Shares - Class A

-0.01 (-1.62%)
Layoffs, Products

Celularity Completes Strategic Review Of 2023 Initiatives

Published: 01/26/2023 23:36 GMT
Celularity Inc - Ordinary Shares - Class A (CELU) - Celularity Completes Strategic Review of 2023 Initiatives, Including Anticipated Biomaterials Production Ramp-up and Pipeline Prioritization of Next-generation Product Candidates.
Celularity Inc - Commercial Biomaterials Business, Degenerative Disease Programs Continue to Gather Momentum.
Celularity - Notified Substantial Portion of Workforce That Their Employment May Be Impacted to Achieve Strategic Objectives.
Celularity Inc - Hopeful That There Will Be No Need to Substantially Reduce Its Headcount.
Celularity Inc - Plans to Complete Required Preclinical Work on Its Ecm Product Candidate Over Next Several Months.
Celularity Inc - Also is Conducting Preclinical Work in Knee Osteoarthritis (koa) Using Its Placenta-derived Exosomes (pexo).
Celularity - to Continue to Partner With Imugene to Utilize Novel Oncarlytics Technology to Prime Solid Tumor Cells to Express Cd19.